

Is Autoantibody Reduction a Key to Managing MG?

Join argenx on Saturday, May 22, 2021, from 10:15 AM-11:00 AM EDT, for an Industry Therapeutic Update from argenx on

Serum Autoantibody Levels and the Role of Antibody Specificity in Myasthenia Gravis

Saturday

22 May

10:15 AM-11:00 AM EDT

Myasthenia gravis (MG) is a rare autoimmune disease that may cause debilitating muscle weakness and has limited management options.

Join us on **Saturday, May 22, 2021, from 10:15 AM-11:00 AM EDT**, for a roundtable seminar, hosted by experts in the management of MG, to review evolving findings on the disease state and pathophysiology of MG, as well as potential treatment strategies, such as autoantibody reduction for management of MG.

The symposium is sponsored by argenx. Please note that this educational symposium is not intended for continuing education credit for healthcare professionals.

This presentation was approved by the Program Committee as an independent activity held in conjunction with ICNMD 2021. It is neither sponsored nor endorsed by ICNMD 2021.

Introducing your roundtable experts:



Heinz Wiendl, MD

Professor in Neurology and Neuroimmunology
Head of Department of Neurology and Translational Neurology
University of Muenster, Germany



Pushpa Narayanaswami, MD

Associate Professor of Neurology
Harvard Medical School
Vice Chair, Clinical Operations
Department of Neurology, Beth Israel Deaconess Medical Center, Boston, USA



Francesco Sacca, MD

Assistant Professor in Neurology at the University "Federico II" of Naples
Assistant Medical Director at the AOU Federico II Naples, Italy

